Llanos AV, Vera GD

Language: Spanish
References: 10
Page: 10
PDF size: 121.95 Kb.

ABSTRACT

It is basic that in the study of patients with pathology of the low genital tract strictly gets applied the quality control, with the purpose of reducing anxiety in patients with minor results or false positives and to establish opportune treatments in patients with major injuries. Esteem that the rates of false negatives in studies of Papanicolaou go from 6 to 50%. The three fundamental aspects to have better results are: 1.- Taking of the sample; 2.- Preparation and 3.- Lecture.
The colposcopy study must be done by enabled personnel, having cito-colpo histology corelation of at least 80%, making treatments based on standards and guides of handling based on 014 NOM and International Federation of Cervical Colposcopy and Pathology of the Inferior Genital Tract and to at least make pursuit of 90% of the patients.
The histopatology study gets to have from 1 to 43% of failure and this can happen in any of the 5 phases: 1.- Pre-pre-analytical: Suitable selection of the study. 2.- Pre-analytical: Identification, preparation and transportation of the sample; 3.- Analytical: Preparation and interpretation of the study. 4.- Post-analytical: Opportune report of the result, copy file and storage of the material. 5.- Post-post-analytical: Treatment based on the result.

REFERENCES

1. Alonso de Ruiz P., Lazcano Ponce E.C., Hernández Ávila M. Cáncer Cervicouterino, Citopatología de cáncer invasor. México D.F. Editorial médica Panamericana. 2005. Segunda edición. Pág. 81-89.

2. Aguilar Pérez J.A., Leyva López A.G., Angulo Nájera D, Salinas A, Lazcano Ponce E.C. Cervical cancer screening: knowledge of Pap smear benefits and utilization in Mexico. Salud Pública. 2003. 37 (1).

3. Lazcano-Ponce E.C., Rascón-Pacheco R.A., Lozano-Ascencio R., Velasco-Mondragón H.E. Mortality from cervical carcinoma in México: Impact of screening, 1980-1990. Acta citológica. 1996. 40 (3): 506-512.

4. Luiz Martins Collaço, Lúcia de Noronha, Diogo Lago Pinheiro, Luiz F. Bleggi-Torres. Quality assurance in cervical screening of a high risk population: A study of 65,753 reviewed cases in Parana screening program, Brazil. Diagnostic Cytopathology. 2005. 33 (6): 441-448.

5. Solomon D, Davey D, Kurman R, Moriarty A, et al. The 2001 Bethesda System. JAMA. 2002. 287:2114.

6. Schiffman M., Adrianza, E. ASCUS-LSIL Triage Study: Design, Methods and Characteristics of Trial Participants. Acta Citológica. 2000, 44(5):726-42.

7. McQueen F., Duvall E. Using a quality control approach to define an 'adequately cellular' liquid-based cervical cytology specimen. Cytopathology 2006, 17 (4):168–174.

8. Williamson S. L. H., Hair T., Wadehra V. The effects of different sampling techniques on smear quality and the diagnosis of cytological abnormalities in cervical screening. Cytopathology. 2003. 8(3):188–195.

9. Modificación a la Norma Oficial Mexicana NOM-014-SSA2-1994, para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino. 31 de mayo 2007.

10. S. B. do Nascimento Tavares, N. L. A. de Sousa, E. J. C. Manrique, Z. B. P. de Albuquerque, L. C. Zeferino †, R. G. Amaral. Rapid pre-screening of cervical smears as a method of internal quality control in a cervical screening programme. Cytopathology. 2008. 19(4): 254–259.